Unknown PHASE2 INTERVENTIONAL 2-arm NCT05658614

Anti-Schistosomiasis Sm14-vaccine in Senegal

Evaluation of Immunogenicity and Safety of a New Vaccine Schedule Using the Vaccine Candidate Sm14 Against Schistosomiasis in Adults With a History of S. Mansoni and / or S. Haematobium Infection.

Sponsor: Oswaldo Cruz Foundation

Conditions Schistosomiasis Haematobium Schistosomiasis Mansoni Vaccination; Infection

Interventions Sm14 recombinant vaccine+ GLA-SE adjuvant

Updated 5 times since 2023 Last updated: Dec 13, 2022 Started: Jul 1, 2022 Primary completion: Sep 15, 2023 Completion: Dec 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05658614, this PHASE2 trial focuses on Schistosomiasis Haematobium and Schistosomiasis Mansoni and remains ongoing. Sponsored by Oswaldo Cruz Foundation, it has been updated 5 times since 2022, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2
Jan 2025 — Sep 2025 [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — Jan 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jan 2023 — Jul 2024 [monthly]

Recruiting PHASE2

First recorded

Jul 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Oswaldo Cruz Foundation

Data source: Oswaldo Cruz Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Saint-Louis, Senegal